ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients
| Status: | Terminated |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | June 2013 |
| End Date: | June 24, 2016 |
Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients
The purpose of this study is to determine the effects of Angiotension Converting Enzyme
Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients
undergoing elective total hip or knee arthroplasty.
Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients
undergoing elective total hip or knee arthroplasty.
Inclusion Criteria:
- Patients electing to undergo primary or revision total hip or knee arthroplasty
- Currently taking an ACE-I
Exclusion Criteria:
- Trauma patients
- Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy
patients, chronic steroid use)
- Patients with history of severe hypertension related illness such as hypertension
associated with stroke or myocardial infarction
- Patients in who continuation of their ACE-I is expressly mandated by their prescribing
physician
We found this trial at
1
site
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Michael Bolognesi, MD
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
